Clinical Trial of BT02 in Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Age ≥18 at the time of signing the informed consent form, male or female; 2. Patients must have histologically or cytologically confirmed diagnosis of advanced solid tumor; 3. Adequate organ and hematologic function; 4. Patients must have at least measurable or evaluable lesion in phase I and measurable lesion in phase II according to RECIST 1.1; 5. ECOG performance status 0\~1; 6. Life expectancy ≥ 3 months; 7. Good compliance and be willing to follow-up visit. Exclusion Criteria: 1. Receive treatment before study as below: a) Previous systematic anti-cancer therapy; 2. Active or prior documented autoimmune disease within past 2 years; 3. History of clinically significant cardiovascular disease; 4. Significant acute or chronic infections; 5. Prior toxicities from anti-cancer therapies have not regressed to grade ≤1 severity; 6. Any prior Grade≥3 irAE while receiving immunotherapy; 7. Unstable brain metastasis or meningeal metastasis with clinical symptoms; 8. Patients with mental disorders or poor compliance; 9. Known alcohol or drug abuse; 10. Other severe systemic diseases or conditions that unsuitable for participating in this study in the opinion of the investigator.